Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for Monday's trading.

KHC data by YCharts

Image placeholder title

Kraft Heinz (KHC) - Get Report: There's a new king in your local packaged food aisle and it's the new Kraft Heinz.

For those not familiar with the story, Heinz was taken private by Warren Buffet in 2013. The company then agreed to merge with Kraft, and that new entity is now trading as KHC.

The new Kraft Heinz is a powerhouse, Cramer told viewers, with a stable of the best brands and a solid management team that knows how to bring those brands to the rest of the world. Shares of Kraft Heinz also sport a 2.9% dividend.

Cramer said he was a big fan of the Heinz management team because they've been aggressively cutting costs, improving margins and bolstering the company's bottom line. Shares currently trade at 23 times estimates, but Cramer said given its international opportunities, $90 or even $100 a share could be in the stock's future.

CFMS data by YCharts

Image placeholder title

ConforMIS (CFMS) - Get Report: The company with the best technology doesn't always win, Cramer told viewers, as he followed up on ConforMIS, the medical device maker with the "holy grail" of knee replacements, a fully customized implant.

Cramer interviewed ComforMIS' CEO July 1 and since then the stock is up a quick 16%. But does it deserve to be?

Cramer said there's no doubt that ConforMIS has the winning technology, which is backed by no less than 470 patents. But it's also up against large, established competitors like Johnson & Johnson (JNJ) - Get Report, Stryker (SYK) - Get Report, Zimmer Biomet (ZBH) - Get Report and Smith & Nephew (SNN) - Get Report.

All of these companies have decades-long relationships with surgeons as well as royalty programs and deep pockets for rewarding repeat business. These rivals are also innovating, having increased the number of implant options from five to 15. That's nowhere near "custom," but it does make ConforMIS a small fish in a very large pond with improving competition.

That said, Cramer noted that it appears ConforMIS is making inroads, having grown revenue by 36%, even with the established headwinds. That means the stock can head still higher.

To read a full recap of "Mad Money" on CNBC, click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had a position in JNJ.